Skip to main content

Table 2 Association between characteristics of articles and statistically significant results or conclusions that favor the test drug: Univariate logistic regression (n = 137).

From: Association of trial registration with the results and conclusions of published trials of new oncology drugs

   Results Favor Test Drug Conclusions Favor Test Drug
Characteristic Category Favorable n/Total n (%) OR
(95% CI)
P Favorable n/Total n (%) OR
(95% CI)
P
Trial registration before publication No 44/83 (53) 1.00   55/83 (66) 1.00  
  Yes 36/54 (67) 1.77 (0.87-3.61) 0.115 43/54 (80) 1.99 (0.89-4.45) 0.093
Year of publication 1996-2002 16/29 (55) 1.00   21/29 (72) 1.00  
  2003-2004 27/40 (68) 1.69 (0.63-4.53) 0.299 30/40 (75) 1.14 (0.39-3.38) 0.809
  2005-2006 18/33 (55) 0.98 (0.36-2.66) 0.961 20/33 (61) 0.59 (0.20-1.71) 0.328
  2007-2008 19/35 (54) 0.97 (0.36-2.59) 0.943 27/35 (77) 1.29 (0.41-4.00) 0.664
Impact Factor* Quartile 1 (1.55-4.44) 15/32 (47) 1.00   19/32 (59) 1.00  
  Quartile 2 (4.45-10.44) 19/33 (58) 1.54 (0.58-4.10) 0.389 22/33 (67) 1.37 (0.50-3.76) 0.543
  Quartile 3 (10.45-17.15) 20/35 (57) 1.51 (0.58-3.96) 0.402 26/35(74) 1.98 (0.70-5.57) 0.197
  Quartile 4 (17.16-52.59) 21/27 (78) 3.97 (1.27-12.43) 0.018 24/27 (89) 5.47 (1.36-22.01) 0.017
Blinding Stringent 18/36 (50) 1.00   25/36 (69) 1.00  
  Not stringent 62/101 (61) 1.59 (0.74-3.42) 0.236 73/101 (72) 1.15 (0.50-2.64) 0.747
Sample Size Quartile 1 (6-122) 10/34 (29) 1.00   19/34 (56) 1.00  
  Quartile 2 (123-352) 22/34 (65) 4.40 (1.59-12.19) 0.004 24/34 (71) 1.90 (0.70-5.16) 0.211
  Quartile 3 (353-772) 22/35 (63) 4.06 (1.48-11.12) 0.006 26/35 (74) 2.28 (0.83-6.30) 0.112
  Quartile 4 (773-8010) 26/34 (76) 7.8 (2.64-23.03) <0.001 29/34 (85) 4.58 (1.43-14.69) 0.011
Primary efficacy outcome Survival 17/30 (57) 1.00   21/30 (70) 1.00  
  Surrogate 63/107 (59) 1.10 (0.48-2.48) 0.828 77/107 (72) 1.10 (0.45-2.67) 0.833
Comparison group Active comparator 35/65 (54) 1.00   45/65 (69) 1.00  
  Placebo 45/72 (63) 0.70 (0.35-1.39) 0.306 53/72 (74) 0.81 (0.38-1.70) 0.571
Sponsored No 14/28 (50) 1.00   15/28 (54) 1.00  
  Yes 66/109 (61) 1.54 (0.67-3.54) 0.314 83/109 (76) 2.77 (1.17-6.56) 0.021
  1. *Only 127 articles were published in journals with a corresponding impact factor.